R1 Therapeutics

R1 Therapeutics is a clinical-stage biopharmaceutical company that develops first-in-class treatments for kidney disease patients.

Health and bio

R1 Therapeutics raised $80.5M in a Series A round announced September 30, 2026, according to clinicaltrialsarena.com. Investors in that round: Samsara Biocapital.

Founders and team

• KP
  Krishna Polu Founder

  source: crunchbase.com
• LM
  L. Mary Smith Founder

  source: crunchbase.com
• BG
  Barbara Gillespie Advisor

  source: crunchbase.com
• BA
  Ben Auspitz Board member

  source: crunchbase.com
• CX
  Chong Xu Board member

  source: crunchbase.com
• GC
  Glenn Chertow Advisor

  source: crunchbase.com
• SM
  Sharon Moe Advisor

  source: crunchbase.com
• TM
  Tom Musgrave Board member

  source: crunchbase.com

Raise history

1. September 30, 2026
   Series A · $80.5M
   SSamsara Biocapital (lead)
   Source: clinicaltrialsarena.com
2. September 22, 2025
   Website created

Investors

• AAbingworth
• CCurie.Bio
• DDaVita Venture Group
• FF-Prime Capital
• SSamsara Biocapital
• SSymBiosis
• UU.S. Renal Care

Related bio health companies

• TTriGemX Bio$94M · Oct 1, 2026
• SSedMed$4M · Oct 1, 2026
• SSharp$328K · Oct 1, 2026
• MM-BasedOct 1, 2026
• AAyna HealthOct 1, 2026
• BBiotia$9M · Oct 1, 2026
• LLinux Laboratories$70M · Sep 30, 2026
• ZZymofixSep 30, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/r1-therapeutics.